Received Oct 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
itchiness and some localized rash at the site of the injection; itchiness and some localized rash at the site of the injection; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site itching in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, 3 days after receiving Arexvy, the patient experienced injection site itching (Verbatim: itchiness and some localized rash at the site of the injection) and injection site rash (Verbatim: itchiness and some localized rash at the site of the injection). The outcome of the injection site itching and injection site rash were not reported. It was unknown if the reporter considered the injection site itching and injection site rash to be related to Arexvy. It was unknown if the company considered the injection site itching and injection site rash to be related to Arexvy. Additional Information: GSK Receipt Date: 05-OCT-2025 The patient developed itchiness and some localized rash at the site of the injection three days after the Arexvy vaccine. The patient was ask could get the delay reaction.